

This PANNA newsletter will also be available at the website: www.pannastudy.com

A newsletter will be issued once per 4 months to update you on the status of the study and inclusions.

Centres

All centres in *The Netherlands; UK; Italy; Germany; Belgium; Ireland; Spain* are open for inclusion (including amendment 3). *UK satellite sites: ethics approval.*


List of compounds under investigation

panna

Etravirine, Intelence, ETV
Rilpivirine, Edurant, TMC278
Abacavir, Ziagen
Fosamprenavir, Telzir, FPV
Tipranavir, Aptivus, TPV
Indinavir, Crixivan, IDV
Raltegravir, Isentress, RAL
Enfuvirtide, Fuzeon, T-20
Maraviroc, Celsentri, MVC
Efavirenz, Stocrin, EFV*
*UK/Ireland only

Inclusions

80 subjects signed informed consent.



New ARVs in the study:

Rilpivirine (Edurant, Eviplera) and **abacavir (Ziagen, Kivexa, Trizivir)** have been added to the list of ARVs under study. The first patient on rilpivirine has already been included!

Closed arms:

Tenofovir, emtricitabine, atazanavir and darunavir arms are closed.

FIRST PUBLICATION

The first paper from data generated by the PANNA network (PK of tenofovir and emtricitabine during pregnancy) has been accepted by AIDS, and has been published online:

[PANNA article epud ahead AIDS](#)

We would like to thank all of you, and especially the co-authors, for your very valuable contributions.

CROI 2013 poster

We have collaborated with the IMPAACT group to write a joint abstract on maraviroc for CROI 2013. We are very pleased that the abstract was accepted as poster, to be presented on Tuesday, March 5.

Investigators meeting

During the CROI 3-6 March 2013, we will plan an investigators meeting. We will inform you on the date and meeting details as soon as possible. And we hope to see many of you in Atlanta.

Plans

Publications on darunavir and atazanavir are being prepared. I hope to send out the drafts for comments early next year.

Further collaboration with the IMPAACT group on combining data from both networks, for abstracts or papers.

Pepe Moltó and Marta Valle are working on a population PK model for darunavir during pregnancy, using the PANNA data.

Have a nice Christmas holiday!

Angela and David

Angela Colbers

Project manager

E-mail: A.Colbers@akf.umcn.nl

Radboud University Nijmegen Medical

Centre, Internal postal code 864,

Department of Pharmacy,

P.O. Box 9101, 6500 HB Nijmegen

Phone: + 31 (0)24 - 361 64 05

Fax: + 31 (0)24- 366 87 55